Cisplatin, Epirubicin, Vindesine combination

The combination of cisplatin, epirubicin, and vindesine (PEV) is a chemotherapy regimen used primarily for the treatment of non-small cell lung cancer (NSCLC). This regimen has been studied in clinical trials, particularly for patients with advanced or inoperable NSCLC. Studies report efficacy in treating NSCLC, with one study showing a 24% response rate in the control arm receiving the PEV regimen. It is noted for its mild acute toxicity, potentially suiting patients with poor performance status. A typical dosing schedule in clinical trials included cisplatin at 60 mg/m² intravenously, epirubicin at 60 mg/m² intravenously, and vindesine at 3 mg/m² intravenously, all administered on day 1 of a 4-week cycle. This multi-targeted approach combines drugs with different mechanisms: * **Cisplatin**: A platinum-based chemotherapy drug that works by damaging DNA and preventing cancer cells from dividing. * **Epirubicin**: An anthracycline antibiotic that interferes with DNA and RNA synthesis in cancer cells. * **Vindesine**: A vinca alkaloid that disrupts microtubules, preventing cell division. Each component works through different mechanisms to inhibit cancer cell growth and proliferation.